Is Enhertu Effective for Lung Cancer?

On January 20, 2022, Bob T. Li and colleagues from Memorial Sloan Kettering Cancer Center published the results of the Phase 2 DESTINY-Lung01 clinical trial in "The New England Journal of Medicine." The study evaluated the efficacy and safety of Enhertu monotherapy in patients with previously treated, HER2-positive advanced non-small cell lung cancer (NSCLC).

DESTINY-Lung01 is an international, multi-center, open-label Phase 2 trial. Patients with previously treated, HER2-positive advanced NSCLC (N=91) received Enhertu monotherapy (6.4 mg/kg every 3 weeks). The primary endpoint was objective response rate (ORR), and secondary endpoints included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).

With a median follow-up of 13.1 months, the primary endpoint ORR was 55%. Secondary endpoints included a median DOR of 9.3 months, a median PFS of 8.2 months, and a median OS of 17.8 months.

Regarding safety, the adverse events confirmed in this trial were consistent with previous findings. The incidence of Grade 3 or higher adverse events was 46%, with neutropenia (19%) being the most common. Drug-related interstitial lung disease (ILD) occurred in 26% of patients, and two deaths were confirmed.

Based on the DESTINY-Lung01 results, Bob T. Li stated that Enhertu monotherapy demonstrated a durable and significant anti-tumor effect in patients with previously treated, HER2-positive advanced NSCLC, with a safety profile consistent with previous clinical trials.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2112431

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer